CBWTF Quote, Financials, Valuation and Earnings

Aurinia Pharmaceuticals, Inc. has a net margin of 51.36% compared to Auxly Cannabis Group, Inc.'s net margin of 42.95%. Auxly Cannabis Group, Inc.'s return on equity of 34.07% beat Aurinia Pharmaceuticals, Inc.'s return on equity of 21.42%.

Auxly Cannabis Group, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Aurinia Pharmaceuticals, Inc. has an analysts' consensus of $16.67 which suggests that it could grow by 6.29%. Given that Aurinia Pharmaceuticals, Inc. has higher upside potential than Auxly Cannabis Group, Inc., analysts believe Aurinia Pharmaceuticals, Inc. is more attractive than Auxly Cannabis Group, Inc..

Auxly Cannabis Group, Inc. has a beta of 1.350, which suggesting that the stock is 35.033% more volatile than S&P 500. In comparison Aurinia Pharmaceuticals, Inc. has a beta of 1.425, suggesting its more volatile than the S&P 500 by 42.546%.

Auxly Cannabis Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aurinia Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Auxly Cannabis Group, Inc. pays -- of its earnings as a dividend. Aurinia Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Auxly Cannabis Group, Inc. quarterly revenues are $29M, which are smaller than Aurinia Pharmaceuticals, Inc. quarterly revenues of $73.5M. Auxly Cannabis Group, Inc.'s net income of $14.9M is lower than Aurinia Pharmaceuticals, Inc.'s net income of $31.6M. Notably, Auxly Cannabis Group, Inc.'s price-to-earnings ratio is 4.96x while Aurinia Pharmaceuticals, Inc.'s PE ratio is 27.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Auxly Cannabis Group, Inc. is 1.52x versus 8.32x for Aurinia Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Instadose Pharma Corp. has a net margin of 51.36% compared to Auxly Cannabis Group, Inc.'s net margin of --. Auxly Cannabis Group, Inc.'s return on equity of 34.07% beat Instadose Pharma Corp.'s return on equity of --.

Auxly Cannabis Group, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Instadose Pharma Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that Auxly Cannabis Group, Inc. has higher upside potential than Instadose Pharma Corp., analysts believe Auxly Cannabis Group, Inc. is more attractive than Instadose Pharma Corp..

Auxly Cannabis Group, Inc. has a beta of 1.350, which suggesting that the stock is 35.033% more volatile than S&P 500. In comparison Instadose Pharma Corp. has a beta of -714.392, suggesting its less volatile than the S&P 500 by 71539.203%.

Auxly Cannabis Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Instadose Pharma Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Auxly Cannabis Group, Inc. pays -- of its earnings as a dividend. Instadose Pharma Corp. pays out -- of its earnings as a dividend.

Auxly Cannabis Group, Inc. quarterly revenues are $29M, which are larger than Instadose Pharma Corp. quarterly revenues of --. Auxly Cannabis Group, Inc.'s net income of $14.9M is higher than Instadose Pharma Corp.'s net income of --. Notably, Auxly Cannabis Group, Inc.'s price-to-earnings ratio is 4.96x while Instadose Pharma Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Auxly Cannabis Group, Inc. is 1.52x versus -- for Instadose Pharma Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Oncolytics Biotech, Inc. has a net margin of 51.36% compared to Auxly Cannabis Group, Inc.'s net margin of --. Auxly Cannabis Group, Inc.'s return on equity of 34.07% beat Oncolytics Biotech, Inc.'s return on equity of -635.07%.

Auxly Cannabis Group, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Oncolytics Biotech, Inc. has an analysts' consensus of $5.49 which suggests that it could grow by 480.67%. Given that Oncolytics Biotech, Inc. has higher upside potential than Auxly Cannabis Group, Inc., analysts believe Oncolytics Biotech, Inc. is more attractive than Auxly Cannabis Group, Inc..

Auxly Cannabis Group, Inc. has a beta of 1.350, which suggesting that the stock is 35.033% more volatile than S&P 500. In comparison Oncolytics Biotech, Inc. has a beta of 0.880, suggesting its less volatile than the S&P 500 by 11.965%.

Auxly Cannabis Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oncolytics Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Auxly Cannabis Group, Inc. pays -- of its earnings as a dividend. Oncolytics Biotech, Inc. pays out -- of its earnings as a dividend.

Auxly Cannabis Group, Inc. quarterly revenues are $29M, which are larger than Oncolytics Biotech, Inc. quarterly revenues of --. Auxly Cannabis Group, Inc.'s net income of $14.9M is higher than Oncolytics Biotech, Inc.'s net income of -$10.5M. Notably, Auxly Cannabis Group, Inc.'s price-to-earnings ratio is 4.96x while Oncolytics Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Auxly Cannabis Group, Inc. is 1.52x versus -- for Oncolytics Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Venus Concept, Inc. has a net margin of 51.36% compared to Auxly Cannabis Group, Inc.'s net margin of -163.68%. Auxly Cannabis Group, Inc.'s return on equity of 34.07% beat Venus Concept, Inc.'s return on equity of -1236.95%.

Auxly Cannabis Group, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Venus Concept, Inc. has an analysts' consensus of -- which suggests that it could grow by 6004.71%. Given that Venus Concept, Inc. has higher upside potential than Auxly Cannabis Group, Inc., analysts believe Venus Concept, Inc. is more attractive than Auxly Cannabis Group, Inc..

Auxly Cannabis Group, Inc. has a beta of 1.350, which suggesting that the stock is 35.033% more volatile than S&P 500. In comparison Venus Concept, Inc. has a beta of -0.111, suggesting its less volatile than the S&P 500 by 111.094%.

Auxly Cannabis Group, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Venus Concept, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Auxly Cannabis Group, Inc. pays -- of its earnings as a dividend. Venus Concept, Inc. pays out -- of its earnings as a dividend.

Auxly Cannabis Group, Inc. quarterly revenues are $29M, which are larger than Venus Concept, Inc. quarterly revenues of $13.8M. Auxly Cannabis Group, Inc.'s net income of $14.9M is higher than Venus Concept, Inc.'s net income of -$22.5M. Notably, Auxly Cannabis Group, Inc.'s price-to-earnings ratio is 4.96x while Venus Concept, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Auxly Cannabis Group, Inc. is 1.52x versus 0.04x for Venus Concept, Inc.. Usually stocks with elevated PS ratios are considered overvalued.